Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NEWS IN BRIEF

This article was originally published in The Silver Sheet

Executive Summary

FDA closes underused pilot Multipurpose Audit Program

You may also be interested in...



Illumina Aims For All-Inclusive Cancer Screen Via New Start-Up

Genetic sequencing company Illumina is betting it can develop the first next-generation sequencing "pan-cancer" screening assay by building a separate company dedicated to the task. The new firm has $100 million in start-up funds and is called Grail.

FDA To Internal Tissue Adhesive Firms: Come In Early With Details

Device firms developing new internal tissue adhesive products should meet with the agency early on and provide detailed descriptions of their product and clinical protocol, agency officials said at a recent meeting.

FDA To Internal Tissue Adhesive Firms: Come In Early With Details

Device firms developing new internal tissue adhesive products should meet with the agency early on and provide detailed descriptions of their product and clinical protocol, agency officials said at a recent meeting.

Related Content

Topics

UsernamePublicRestriction

Register

MT038402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel